Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Clinical Profile of Exenatide To understand subsequent innovations, its helpful to summarize exenatides clinical profile (as the first GLP-1 RA): Efficacy: In trials, twice-daily exenatide (10 g BID) typically reduced HbAc by approximately 0.8%1.0% more than placebo by 30 weeks ( [61] ) ( [101] )
For example, immuno-oncology drugs, in the form of programmed cell death protein-1 (PD-1) antagonists, have a slower growth rate, with projections of a CAGR of 4.7% and a market size of $51 billion in 2029, nearly half of the GLP-1 agonist market ( see Figure 1) ,according to estimates from GlobalData
90 OtaK.ItoK.AkahiraJ.SatoN.OnogawaT.MoriyaT.et al (2007)
In conclusion, the benefits of GLP-1RAs in MASLD are promising, and background therapy involving metabolic modulation may represent one of the future therapeutic paradigms
US$ 28.17
US$ 20.60
US$ 22.68
US$ 29.79
US$ 21.29
